Did You Know?

Editor’s Picks

Latest News

Enhanced Group Announces $50 Million Strategic Financing Led by Enhanced Co-Founder and Chairman Christian Angermayer; Management Expects Company Fully Funded Through Profitability

Financing Led by Christian Angermayer's Family Office Apeiron Investment Group with Participation from Co-Founder and CEO Maximilian Martin and Leading...

Nabsys Announces Advancements in Detection of Repeat Contraction and Expansion Disorders Via Electronic Genome Mapping in Collaboration with Leading European Institutions

Collaboration with Leiden University Medical Center (LUMC) will explore application of electronic genome mapping (EGM) in facioscapulohumeral muscular dystrophy (FSHD)Poster presentation...

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating...

ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea 

Integration supports remote patient monitoring and value-based care ProSomnus RPMO2 OSA Device System RPMO2 OSA Device System The only medical...

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company...

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time...

error: Content is protected !!